A closer look at the baseline-observation-carried-forward (BOCF)
Hong Liu-Seifert, Shuyu Zhang, Deborah D'Souza, Vladimir Skljarevski, Hong Liu-Seifert, Shuyu Zhang, Deborah D'Souza, Vladimir Skljarevski
Abstract
Purpose: The baseline-observation-carried-forward (BOCF) approach is one method to handle missing data from early treatment discontinuation. We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation.
Methods: Two duloxetine chronic pain trials (placebo-controlled) were used to examine the impact of different analytical methods on study outcome. Reasons for discontinuation were categorized as treatment-related and nontreatment-related. Missing data in the primary efficacy outcome were handled using five statistical methods: mixed-model repeated measures (MMRM), last-observation-carried-forward (LOCF), BOCF, modified BOCF (mBOCF, discontinuation due to treatment-related reasons, ie, adverse events [AEs] or lack of efficacy), and aeBOCF (discontinuation due to AEs only).
Results: Duloxetine was superior to placebo on mean change from baseline in Brief Pain Inventory average pain rating, using MMRM (study 1, P = 0.004; study 2, P < 0.001), LOCF (study 1, P = 0.019; study 2, P < 0.001), BOCF (study 1, P = 0.019; study 2, P = 0.013), and mBOCF (study 1, P = 0.041; study 2, P = 0.005). Using aeBOCF, duloxetine was superior to placebo in study 2 (P = 0.005) and numerically better in study 1 (P = 0.075).
Conclusion: Due to the different assumptions made by various methods regarding accounting for missing data, the analytical methods chosen may influence the interpretation of study results. Consideration should be given to the effect of actual treatment outcomes from patients. Employing different statistical approaches such as sensitivity analyses may help to assess the robustness of the study results and provide a more accurate reflection of the treatment outcome.
Keywords: discontinuation; pain; statistical; treatment-related.
References
- Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat. 2002;12(2):207–226.
- Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2):93–106.
- Mallinckrodt CH, Sanger TM, Dubé S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754–760.
- Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42(4):303–319.
- Shao J, Jordan DC, Pritchett YL. Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat. 2009;19(4):672–684.
- Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine. 2009 In press.
- Chappell AS, Desaiah D, Liu-Seifert H, et al. Duloxetine 60 to 120 mg once daily versus placebo in the treatment of patients with osteoarthritis knee pain. [Poster] Presented at the American Academy of Pain Medicine (AAPM) – 25th Annual Meeting; Honolulu, HI, USA. Jan 28–31, 2009.
- Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121.
- Andersen JW, Van Der Horst C, Gorski H, Fass RJ. Conference on Retroviruses and Opportunistic Infections. The association of site with early study discontinuation on HIV clinical studies in the protease inhibitor era: DACS200. Program Abstr 8th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 8th 2001 Chic Ill; 2001 Feb 4–8; p. 188. (abstract no. 486)
- Anderson JW, Fass R, van der Horst C. Factors associated with early study discontinuation in AACTG studies, DACS 200. Contemp Clin Trials. 2007;28(5):583–592.
Source: PubMed